eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

SCImago Journal & Country Rank
 
4/2020
vol. 19
 
Share:
Share:
more
 
 
Special paper

Age of natural menopause onset in BRCA1/2 carriers – systematic review and meta-analysis

Łukasz Kępczyński
1
,
Katarzyna Połatyńska
2
,
Anna Nykel
1
,
Jordan Sałamunia
3
,
Tadeusz Kałużewski
3
,
Andrzej Kużawczyk
4
,
Agnieszka Gach
1

1.
Department of Genetics, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
2.
Department of Neurology, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
3.
Laboratory of Medical Genetics of the “Genos” Partnership R&D Division, Lodz, Poland
4.
Institute IURISMED – Independent Medical Examiners, Kutno, Poland
Menopause Rev 2020; 19(4): 171-173
Online publish date: 2021/01/07
Article file
- Age of natural.pdf  [0.08 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

Introduction

„Breast cancer genes” BRCA1 and BRCA2 are by far the most widely studied human genes, and consequences of germline pathogenic variants of both genes for cancer risk are very well described [1]. Non-oncological implications of germline BRCA1 and BRCA2 genes, complicating reproductive health, including early natural menopause, reduced ovarian reserve and unresolved association between BRCA1 and BRCA2 pathogenic variants, premature ovarian failure and CGG repeat number in FMR1 gene, are far less described [2-6].

Woman’s reproductive lifespan is limited by the age of menarche and age of natural menopause (ANM). Timing of both events are determined by genetic and environmental factors, with relatively high heritability for ANM, estimated on around 50% [7]. At least intragenic 3 loci (SYCP2L, UIMC1, and MCM8) and a least 1 intergenic locus (13q34) are associated with ANM across different ethnic populations [8], and can be treated as quantitative trait loci (QTL) for ANM. Loci for premature menopause were also identified, with most widely studied association between premature ovarian failure (POF) and number of CGG repeats in FMR1 gene [9].

The influence of germinal BRCA1 and BRCA2 on AMN remains inconclusive and controversial. Hence, we conducted a comprehensive systematic review and meta-analysis of BRCA1 and BRCA2 pathogenic variants on ANM.

Material and methods

PubMed database was searched for abstracts by two reviewers (ŁK and KP) using the keywords: (“BRCA1” OR “BRCA2” OR “hereditary breast cancer”) AND (“menopause”). We identified 193 citation; both reviewers independently reviewed potentially relevant studies subsequently excluded studies which were not case-control, cohort or cross-sectional studies. Additionally, reference lists from systematic reviews or meta-analyses, dealing with the topic of menopause and BRCA1 and BRCA2 germinal pathogenic variants, were also checked to identify eligible studies. Studies dealing only with risk-reducing salpingo-oophrectomy (RRSO) and influence of ANM on breast and/or ovary cancer risk were excluded. Two studies (Table 1) not reporting dispersion measures and not reporting ANM in control group were left in tabular summary, yet were excluded from meta-analysis. Discrepancies in retrieved list were resolved by consensus. We also included our original, unpublished data from families, affected by BRCA1 or BRCA2 pathogenic variants, consisted of at least two postmenopausal female siblings with differing variant status (Table 2). None of our patients undergone RRSO prior to natural menopause. As most of the data reported median and range for ANM, we estimated mean and standard deviation using Hozo et al. approach [10]. Meta-analysis was done using random effects model on standardized mean differences. Statistical analysis was conducted using R (version 3.6.1. The R Foundation for Statistical Computing).

Table 1

Studies included in systematic review and meta-analysis

StudyBRCA1/2 positiveBRCA1 positiveBRCA2 positiveControlsGeographical region
Rzepka-Górska et al., 2006 Median = 45.5 [45]
(Range: 39-52)
Median = 45.5 [45]
(Range: 39-52)
NA1 Median = 48.2 [90]
(Range: 43-53)
Poland
Lin et al., 20122 Median = 49 [166]
(Range: 26-55)
Median = 48 [94]
(Range: 26-55)
Median = 49 [72]
(Range: 28-53)
Median = 53 [639]
(Range: 18-53)
United States (California)
Collins et al., 20133 NA Median = 51.[445] Median = 51 [374] Median = 52 [559]
Median = 51 [462]
Australia and New Zeland
Finch et al., 2013 Mean = 50.3 [207]
(Range: 38-53)
Mean = 49.9 [109]
(Range: 39-65)
Mean = 50.8 [95]
(Range: 38-59)
Mean = 49.0 [242]
(Range: 30-63)
Mean = 48.8 [126]4
(Range: 30-57)
Mean = 49.2 [113]5
(Range: 36-62)
Canada and United States
Tea et al., 20136 NA Mean = 40.7 [50] Mean = 46.8 [49] NA Austria
van Tilborg et al., 2016 Median = 53 [1208]
(Range: 28-59)
NA NA Median = 53 [2211]
(Range: 35-62)
The Netherlands
Kępczyński et al., 2020
(this study)
Mean = 48.4 [7]
(Range: 43-52)
Mean = 48.4 [7]
(Range: 43-52)
NA7 Mean = 46.2 [9]
(Range: 41-52)
Poland

1 All cases were attributed to BRCA1 mutations, 2 range derived from Figures 3 and 4, 3 no dispersion measure nor range was given – excluded from analysis, 4 controls for BRCA1 positive group, 5 controls for BRCA2 positive group, 6 mean calculated as mean of menarche in whole group + mean reproductive lifespan, no actual data nor dispersion measure was given – excluded from analysis, 7 only one family with BRCA2 mutation

Table 2

Characteristics of BRCA1/2 positive probands and their BRCA1/2 negative siblings

FamilyBRCA1/BRCA2 pathogenic variant NM_007294.4Cancer status of affected sisterAge of natural menopause
BRCA1/2(+) sister(s)BRCA1/2(–) sister(s)
I BRCA1: c.5266dupC pre BRC 43 50
II BRCA1: c.5266dupC post BRC 44 46
42
III BRCA1: c.5266dupC pre BRC 50 41
IV BRCA1: c.1687C>T pre BRC 48 44
unaffected 52
V BRCA1: c.181T>G pre BRC 52 45
48
VI BRCA2: c.6982G>T pre BRC 50 48
52

[i] BRCA1 variants nomenclature based on NM_007294.4 transcript sequence, BRCA2 variants based on NM_000059.3 transcript sequence, pre BRC – premenopausal breast cancer, post BRC – postmenopausal breast cancer

StudyBRCA1/2 positiveControlStandardized mean differenceSMD95% CIWeight
TotalMeanSDTotalMeanSD
Rzepka-Gorska et al., 2006 (Poland)4545.503.43599048.102.6404/f/fulltexts/PM/42760/MR-19-42760-inline001_min.jpg–0.88[–1.26; –0.51]20.3%
Lin et al., 2013 (US, California)16644.677.707263944.089.47550.06[–0.11; 0.24]23.1%
Finch et al., 2013 (Canada and US)10947.854.001924247.738.64430.02[–0.21; 0.24]22.5%
van Tilborg et al., 2016 (The Netherlands)120848.178.2120221150.717.0917–0.34[–0.41; –0.27]23.8%
Kepczynski et al., 2020 (Poland)748.433.6450946.223.63240.57[–0.44; 1.59]10.3%
Random effects model15353191–0.18[–0.78; 0.42]100.0%
Prediction interval[–1.77; 1.41]
Heterogeneity: I2 = 89%, τ2 = 0.2025, p < 0.01

Results and discussion

Our database search retrieved 193 articles by initial strategy, and 6 studies, combining data from 2121 germinal BRCA1 and BRCA2 pathogenic variant carriers and 3741 control subjects [11-16]. Four of the studies used Kaplan-Meier approach to assess the differences between carriers and non-carriers [12, 13, 16], two studies were excluded from meta-analysis, as they reported no dispersion measures (and we were unable unambiguously derive those data from Figures) [13] or did not report data from control group [15]. We also included original data from 7 pathogenic variant carriers and 9 non-carrier siblings, summarized in Table 2. Studies included in presented meta-analysis combined data from 1535 germinal BRCA1 and BRCA2 pathogenic variant carriers and 3191 control individuals. Results of preformed meta-analysis are presented in Figure 1. Results only from group affected with BRCA1 pathogenic variant was similar to group combining carriers of either pathogenic variants (data not shown). Shortage of data from carriers of germinal BRCA2 pathogenic variants did not enabled draw significant conclusions.

Three studies reported association BRCA1 and BRCA2 with premature menopause [11, 12, 14], two studies reported no evidence of that association [13, 16]. Meta-analysis results does not support the hypothesis of association between germinal pathogenic variants of “breast cancer genes” and premature menopause. Nevertheless, data from all included studies are prone to selection biases as cessation of observation due to RRSO or cancer-related and treatment-related menopause. Only carefully designed prospective study may resolve the true association between BRCA1 and BRCA2 and early menopause.

Disclosure

The authors report no conflict of interest.

References

1 

Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017; 317: 2402-2416.

2 

de la Noval BD. Potential implications on female fertility and reproductive lifespan in BRCA germline mutation women. Arch Gynecol Obstet 2016; 294: 1099-1103.

3 

Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 2010; 28: 240-244.

4 

Cordeiro Mitchell CN, McGuinness B, Fine E, et al. Navigating the body of literature assessing BRCA1/2 mutations and markers of ovarian function: a systematic review and meta-analysis. J Assist Reprod Genet 2020; 37: 1037-1055

5 

Weghofer A, Tea MK, Barad DH, et al. BRCA1/2 mutations appear embryo-lethal unless rescued by low (CGG n<26) FMR1 sub-genotypes: explanation for the „BRCA paradox”? PLoS One 2012; 7: e44753.

6 

Laitman Y, Ries-Levavi L, Berkensdadt M, et al. FMR1 CGG allele length in Israeli BRCA1/BRCA2 mutation carriers and the general population display distinct distribution patterns. Genet Res (Camb) 2014; 96: e11.

7 

Murabito JM, Yang Q, Fox C, et al. Heritability of age at natural menopause in the Framingham Heart Study. J Clin Endocrinol Metab 2005; 90: 3427-30.

8 

Carty CL, Spencer KL, Setiawan VW, et al. Replication of genetic loci for ages at menarche and menopause in the multi-ethnic Population Architecture using Genomics and Epidemiology (PAGE) study. Hum Reprod 2013; 28: 1695-706.

9 

Noto V, Harrity C, Walsh D, Marron K. The impact of FMR1 gene mutations on human reproduction and development: a systematic review. J Assist Reprod Genet 2016; 33: 1135-1147.

10 

Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.

11 

Rzepka-Górska I, Tarnowski B, Chudecka-Głaz A, et al. Premature menopause in patients with BRCA1 gene mutation. Breast Cancer Res Treat 2006; 100: 59-63.

12 

Lin WT, Beattie M, Chen LM, et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer 2013; 119: 1652-1659.

13 

Collins IM, Milne RL, McLachlan SA, et al. Do BRCA1 and BRCA2 mutation carriers have earlier natural menopause than their noncarrier relatives? Results from the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer. J Clin Oncol 2013; 31: 3920-3925.

14 

Finch A1, Valentini A, Greenblatt E, et al. Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril 2013; 99: 1724-1728.

15 

Tea MK, Weghofer A, Wagner K, Singer CF. Association of BRCA1/2 mutations with FMR1 genotypes: effects on menarcheal and menopausal age. Maturitas 2013; 75: 148-151.

16 

van Tilborg TC, Broekmans FJ, Pijpe A, et al. Do BRCA1/2 mutation carriers have an earlier onset of natural menopause? Menopause 2016; 23: 903-910.

Copyright: © 2021 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe